CJC-1295 (no DAC) / Mod GRF 1-29
Growth hormone axis · By Preptide Pro editorial team · Last updated
CJC-1295 (no DAC) / Mod GRF 1-29 is a growth hormone axis peptide, and it is not FDA-approved. A modified version of the first 29 amino acids of GHRH without the albumin-binding group. It has a short action and little formal clinical research.
Not FDA-approvedChemistry (PubChem)
No matching PubChem compound record was found under this name.
Is CJC-1295 (no DAC) / Mod GRF 1-29 FDA-approved?
Not FDA-approved. No matching NDA or BLA was found in openFDA (Drugs@FDA).
How much research is there on CJC-1295 (no DAC) / Mod GRF 1-29?
PubMed lists 206 records for “"modified GRF" OR "GRF 1-29" OR CJC-1295”, of which 11 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| Detection of CJC-1295 in Equine Plasma by ELISA. | Drug Test Anal | 2026 Oct 14 |
| Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. | Sex Med Rev | 2026 Sep 30 |
| Peptide Supplements and Their Therapeutic Applications in Sports Medicine. | Am J Sports Med | 2026 Aug 11 |
| Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. | Sports Med | 2026 Aug |
| A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. | J Sports Med Phys Fitness | 2026 Jul |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.